BRCA1 and cancer: Aberrant degradation of nascent DNA by MRE11 was observed in tumor suppressor BRCA1/2-deficient cells, and abrogation of MRE11 activity is linked to PARP inhibitor resistance in cancer chemotherapy2,3.